Humacyte (HUMA) Projected to Announce Quarterly Earnings on Tuesday

Key Points

• Humacyte is expected to report Q3 2026 results before market open on November 10, with analysts forecasting a loss of $0.09 per share and revenue of $0.77 million. Its earnings call is scheduled for 8:00 a.m. ET.
• In its previous quarter, Humacyte posted a $0.16-per-share loss, wider than the $0.11 consensus estimate, and revenue of $0.41 million versus expectations of $1.04 million.
• Analyst views are mixed but lean positive: MarketBeat reports a “Moderate Buy” consensus from six Buy, one Hold, and one Sell rating, with an average price target of $4.96.

Humacyte (NASDAQ:HUMA - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $0.77 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. The company had revenue of $0.41 million during the quarter, compared to analysts' expectations of $1.04 million. On average, analysts expect Humacyte to post ($0.40) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Humacyte Stock Up 10.7%

HUMA stock opened at $0.44 on Wednesday. The company's 50 day moving average price is $0.51 and its 200 day moving average price is $0.80. The firm has a market capitalization of $122.37 million, a price-to-earnings ratio of -0.90 and a beta of 2.64. Humacyte has a fifty-two week low of $0.34 and a fifty-two week high of $1.56. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21.

Analyst Upgrades and Downgrades

Several research firms have commented on HUMA. HC Wainwright reiterated a "buy" rating on shares of Humacyte in a report on Friday, October 16th. Barclays upgraded shares of Humacyte to a "hold" rating in a report on Wednesday, October 7th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Humacyte in a research report on Friday, October 2nd. Benchmark decreased their price objective on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating for the company in a research report on Thursday, August 13th. Finally, BTIG Research restated a "buy" rating and issued a $2.00 price target on shares of Humacyte in a research note on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $4.96.

About Humacyte

Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company's platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.

Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.